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Epigenetic modiﬁcations are hereditable and modiﬁable factors that do not alter the DNA sequence. These
epigenetic factors include DNA methylation, acetylation of histones and non-coding RNAs. Epigenetic factors
havemainly been associatedwith cancer but also with other diseases and conditions such as diabetes or obesity.
In addition, epigenetic modiﬁcations could play an important role in cardiovascular diseases, including stroke.
We review the latest advances in stroke epigenetics, focusing on DNA methylation studies and the future
perspectives in this ﬁeld.
© 2017 Krupinski et al.. Published by Elsevier B.V. on behalf of the Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Stroke is the 2nd leading cause of deathworldwide. It is also the lead-
ing cause of disability in adults, with 20% of stroke survivors needing help
to walk and being dependent on others to perform daily tasks. Stroke
survivors therefore require signiﬁcant social and healthcare resources [1].
In the elderly population of 15 European countries during the year
2000, estimates showed 2,700,000 recurrent stroke cases, and 536,000
incident stroke cases per year [2]. The total number of deaths due to
stroke in the total European Union (EU) members is estimated at
508,000/year. Given that age is one of most important risk factors for
stroke, the aging of the world population implies a growing number of
people at risk. An international comparison of stroke cost studies
showed that 0.27% of domestic product was spent on stroke care by
national health systems, and stroke care accounted for approx. 3% of
total healthcare expenditure [3].
1.1. Stroke Recurrence
The risk of ischemic stroke recurrence after a ﬁrst stroke is high,
especially in the early stages, being around 6–12% within the ﬁrst year
of the initial stroke [4]. Moreover, stroke patients also have a high risk
of developing other vascular diseases such as acute myocardial
infarction and vascular death. Data suggest that within 10 years of
having an ischemic stroke or Transient Ischemic Attack (TIA), around
60% of patients will die and 54% will experience a new vascular event.
1.2. Stroke Functional Outcome
The variability in functional status and neurological outcome after
stroke can be inﬂuenced by many factors, including age, haemorrhagic
transformation (HT), infarct size and location, or the efﬁciency of
revascularisation (by thrombolytic drugs or mechanical thrombectomy)
[5,6]. Results fromprevious studies suggest that basal glucose, age, hyper-
tension and arterial revascularisation success accounted for 33% of the
variability in neurological outcome during the acute phase of stroke (at
24 h). However, 57% of the neurological variability remains unexplained.
In addition, 25% of neurological outcome could be explained by common
polymorphisms or single nucleotide polymorphisms (SNPs) [7].
1.3. Stroke Genetics
Stroke is inﬂuenced by genetic risk factors. These genetic risk factors
can affect stroke occurrence, acute outcome, long-term outcome and
vascular recurrence, among others. Interestingly, different molecular
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pathways modulate these processes, suggesting that different genetic
risk factors inﬂuence these processes.
Different Genome Wide Association studies (GWAs) have been
performed in ischemic stroke and different loci have been associated
with the risk of suffering an ischemic stroke. Speciﬁcally, 3 genes have
been associated with atherothrombotic stroke subtype (HDAC9, CDKN
(locus 9p21) and TSPAN2), 2 genes with cardioembolic stroke subtype
(PITX2 and ZFHX3), and 2 genes with young strokes (ABO and
MMP12). Other GWAs analyses have found other genes and loci
associated with stroke (PRKCH, NINJ and genetic locus 6p21.1),
although further studies are needed to conﬁrm those results [8–17].
In relation to stroke recurrence several studies in Asian populations
[18,19] associations of ANRIL and NINJ2 polymorphisms with vascular
recurrence. Other studies in Caucasian populations found associations
between CRP and MGP polymorphisms and recurrent stroke [4,20].
However, other studies have not observed those associations [21].
Different polymorphisms in the genes MMP2, COX-2, GPII, and TP53
have been associatedwith post-stroke outcome [22–24], although these
results have not been consistently replicated.
1.4. Epigenetics
The risk associated with the genetic background in stroke is in the
order of 37.9% [25,26]. However, the genetic risk associated with the
variants found to date only account for 5–10% of that genetic risk [25].
Therefore, there are more genes and heritable risk factors associated
with stroke that have not yet been discovered. One of these possible
heritable changes could be associated with epigenetic modiﬁcations.
Epigenetic mechanisms are known to alter gene expression or
cellular phenotype [27].
There are three major components of epigenetic modiﬁcation:
a) methylation, b) histone modiﬁcations and c) non-coding ribonucleic
acid (RNA) interference. Both methylation and histone modiﬁcations
join hands to provide a dynamic epigenetic code. Along with non-
coding RNAs (ncRNAs) and certain interacting proteins, these modiﬁca-
tions regulate the transcription process.
1.4.1. Methylation
DNAmethylation andmodiﬁcations in histone proteins are themost
intensively studied among the major epigenetic modiﬁcations. DNA
methylation occurs when a methyl group is added to a cytosine nucleo-
tide that precedes guanines (so-called CpG islands or CpG sites).
A CpG island may be deﬁned as the DNA region of at least 500 base
pairs with a CG content of N55% [28]. Methylation of CpG islands is
catalysed by a family of enzymes, the DNA methyl transferases
(DNMTs). DNMT1 maintains cytosine methylation through mitotic
and meiotic cell divisions. Methylation of a CpG island within gene
promoters is commonly associated with repressed gene expression, as
it impedes the binding of transcription factors.
1.4.2. Other Epigenetic Modiﬁcations
Post-translational histone modiﬁcations, such as methylation and
acetylation of lysine residues on histone tails, affect gene expression
mainly by altering chromatin structure [27]. Acetylation is brought
about by histone acetyltransferase (HATs) enzymes and deacetylation
by histone deacetylases (HDACs) [29,30].
Small non-coding RNAs (sncRNAs) are epigenetic elements (b30
nucleotides) with a post-transcriptional biological function. The major
components of the sncRNA family, the microRNAs (miRNAs), generally
interact speciﬁcally with the 3′ untranslated region of a target mRNA to
induce its cleavage and degradation, or via a translational repression of
gene expression [31,32].
Epigenetic mechanisms are known to alter gene expression [27].
However, other underlying mechanisms such as genetic variations
could modify DNA CpG sites modifying the epigenetic regulation of
genes [33]. Knowing these mechanisms could be important in ﬁnding
new treatments for stroke and other cardiovascular diseases [34].
1.5. Epigenome-Wide Association Studies (EWAS). Technical Aspects of the
Methylation Chips
Genome-wide association studies (GWAS) have been powerful tools
in the identiﬁcation of the most common genetic variants associated
with a multitude of complex traits including common diseases. In
contrast, the systematic assessment of epigenetic variation has lagged
behind. Technological advances in high-throughput DNA analysis have
facilitated the genome-wide examination of epigenetic modiﬁcations,
primarily DNA methylation. Epigenome-wide association studies
(EWAS) have provided systematic, large-scale association testing with
disease phenotypes. The latest EWAS arrays (the Inﬁnium EPIC
HumanMethylation BeadChip (Illumina)) can detect the methylation
levels of N800,000 CpG sites across the genome.
Numerous diseases, exposures and lifestyle factors have been inves-
tigated by EWAS, with several signiﬁcant associations now identiﬁed.
However, much like the GWAS studies, EWAS are likely to require
large international consortium-based approaches to reach the numbers
of subjects, and statistical and scientiﬁc rigour, required for robust
ﬁndings.
1.5.1. Tissue-Speciﬁc Methylation
DNA methylation is strongly inﬂuenced by the tissue analysed and
the environment. In fact, epigenetics is one of the metabolic factors
that regulate the different expression pattern of the cells and tissues.
Consequently, epigenetic studies should be performed in the key tissue
for the disease or the condition. In addition, in the case of blood samples
there are different cell types with different DNA methylation pattern.
This should be taken into consideration before EWAs analysis in order
to normalise the results.
Taking into consideration the role of genetics in the risk of stroke but
also the outcome after a stroke, DNA methylation could be associated
with the occurrence of stroke, with stroke recurrence and with
functional outcome after stroke.
2. DNA Methylation in Stroke
2.1. Methods
An extensive literature search was performed, up to October 2017,
on PubMed with the following combination of key words: “Epigenetics
and stroke” and “EWAs and stroke”. For the combination of “Epigenetics
and stroke” we found 128 papers and 4 for the combination of “EWAs
and stroke”. Three papers were common between the two combina-
tions of words (Fig. 1). Two researchers independently check the
papers. We selected the papers that 1) were performed using human
samples and an EWAs approach, and 2) papers that analysed the global
methylation pattern of stroke patients. Finally, eight papers were
included in the current revision (Fig. 1).
In addition, we included examples of other diseases or studies in
animal models that support the results observed in stroke.
2.2. Stroke DNA Methylation Risk Factor
Epigenetic modiﬁcations, speciﬁcally DNA methylation, are
inﬂuenced by environmental factors and are heritable modiﬁcations. It
has been observed that different levels of DNAmethylation are associat-
edwith the risk of diseases such as cancer, diabetes, obesity, atheroscle-
rosis or arterial hypertension [35].
Human and mouse studies have observed global DNA hypermethy-
lation of cytosines in CpGs as an accompanying feature of atherosclero-
sis [35–37]. Indeed, a positive correlation between DNA methylation
and atherosclerotic lesion grade was discovered by using genome-
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wide DNA methylation sequencing (i.e., bisulphite sequencing) of
healthy and atherosclerotic human aortas [35,38] and conﬁrmed by
EWAS validation. Differentially methylated regions within the loci of
cardiovascular disease associated genes in endothelial cells isolated
from atherothrombotic regions of porcine aortas were also discovered
using methylated DNA sequencing [39].
Furthermore, global DNA hypermethylation has been observed in
peripheral lymphocytes of patients with cardiovascular disease, and
may be linked to the inﬂammatory activity of innate immune cells [40].
Interestingly, global methylation was not found to be associated
with stroke subtypes measured by luminometric methylation assay
(LUMA) of blood DNA samples [41]. In contrast, other studies have
observed an association of global hypomethylation and higher risk of
stroke [42].
A recent study analysed a Swedish population of 729 subjects, 48 of
them with myocardial infarction and 27 with previous stroke, using an
EWAs approach. The authors found a different methylation pattern in
211 CpG sites associated with myocardial infarction. However, they
did not ﬁnd any signiﬁcant association with stroke [43].
The DNAmethylation levels change during aging, and there is usual-
ly a global hypermethylation in older people. In fact, is possible to calcu-
late the biological age using the methylation levels of several CpG sites.
In the ﬁeld of stroke, it has been shown that the biological age
(different from chronological age) of stroke patients measured by
DNA methylation is different between cases suffering stroke and
healthy controls. The stroke patients were biologically older than
healthy controls [44]. The authors of this study calculated the
“epigenetic age” or “biological age” using the DNAm levels of whole-
blood DNA and using the Hannum method [44,45]. This method is
based on the methylation levels from 71 methylation probes from a
450 K EWAS Methylation array.
The authors analysed a group of 123 stroke cases and controls
matched by chronological age and they found that ischemic stroke
patients were biologically on average 2.5 years older than healthy
controls, indicating that biological agemeasuredwith DNAmethylation
levels could be a stronger risk factor for ischemic stroke than chronolog-
ical age.
2.3. DNA Methylation and Stroke Recurrence
Several independent papers have observed the role of DNAmethyl-
ation in the risk of newvascular events (vascular recurrence) after a ﬁrst
ischemic stroke. Hypomethylation of the ABCB1 promoter has been
associated with poor response to clopidogrel in Chinese ischemic stroke
patients with the CYP2C19*1/*1 genotype [46]. ABCC3, another member
of the ABC family, has been associatedwith the efﬂux of clopidogrel and
its antiplatelet activity [47,48]. However, ABCC3 promoter methylation
and down-regulation of ABCC3 mRNA had no signiﬁcant association
with clopidogrel response [49].
A recent epigenome-wide study revealed that lower methylation of
cg03548645 within the TRAF3 body was associated with increased
platelet aggregation and vascular recurrence in ischemic stroke pa-
tients treated with clopidogrel [50]. The authors hypothesised that
higher TRAF3 expression due to decreased methylation may lead to
an increase in CD40 signal pathway interfered platelet-platelet interac-
tions [51,52].
In another study from the same group they observed that higher
methylation levels of cg04985020 (PPM1A gene) were associated with
vascular recurrence in patients treated with aspirin [53]. They analysed
38 ischemic stroke patients with an EWAS array and detected N450,000
CpG sites. Secondly, they performed a replication analysis in 289
new ischemic stroke patients. This analysis conﬁrmed that the role of
PPM1A methylation levels in the risk of new vascular events after
stroke involves the regulation of transforming growth factor. They
hypothesised that higher methylation of PPM1A was associated with
(TGF)-β1 signalling and plasminogen activator inhibitor-1 transcription
[54].
Words used: stroke and 
EWAss
Words used: stroke and 
epigenecs
128 papers found 4 papers found
129 papers
Selecon 
8 papers included in the 
revision
Fig. 1.Work ﬂow showing the selection of the studies included in the present review.
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2.4. DNA Methylation of Functional Outcome
In relation to functional outcome, only a couple of studies have been
performed to evaluate the association of DNA methylation levels and
post-stroke functional outcome. However, it seems that DNAmethylation
could have an important role in this condition. In studies with animal
models of ischemia, it has been observed that epigenetic mechanisms
are associated with neurological outcome, thereby indicating that epige-
netic processes may play a signiﬁcant role in post-stroke outcome [55].
Pilot studies with 700 stroke patients and EWAS data that analysed
450,000 CpG islands across the genome showed that several genes
had an altered methylation associated with neurological outcome
after stroke [56]. However, these results should be replicated in
independent cohorts.
In addition, a recently published paper observed that biological age, as
measured by DNAmethylation, was associated with poor functional out-
come in stroke patients [57]. The authors calculated the epigenetic age as
the sum of the beta values multiplied by the reported effect sizes follow-
ing a previously reported protocol [44,45]. They observed that this epige-
netic age was a better predictor of functional stroke outcome at the third
month compared to chronological age. Interestingly, the same authors ob-
served an association of epigenetic age with stroke risk [44].
2.5. Challenges and Solutions for Studying Epigenetics in Stroke Patients
Epigenetic analysis in stroke entails the challenge of testing the key
tissue for the disease. It is difﬁcult to study brain necrotic samples or
human blood vessels; consequently, epigenetics studies are performed
on blood samples. This could be a problem due to: a) the tissue not
being the key tissue for the disease, and b) the variability in the cell
composition of the blood samples.
For the ﬁrst point, transcriptomic and proteomic analyses have
demonstrated that blood is an important tissue for stroke, probably
due to the role of leukocytes in the inﬂammation process of atheroscle-
rosis and neurological outcome after stroke [58,59].
For the second point, the epigenetic results can be normalised
whenever the cell count data for a sample is available. In addition, for
EWAS analysis, R packages (WateRmelon) [60,61] incorporate statisti-
cal normalization for blood sample results.
3. Summary and Outlook
The use of epigenetics studies in stroke is an emerging ﬁeld of inter-
est. It seems that epigenetics plays an important role in this disease in
different stages, prior to the ischemic attack and after the ischemic
stroke. Speciﬁcally, DNA methylation could be associated with the risk
of stroke, with stroke recurrence and with the functional outcome
after stroke.
DNAmethylation is a modiﬁable regulation; it is possible that in the
future methylated or unmethylated genes could be a drug target for
stroke treatment. In fact, there are now effective neuroprotective
drugs that can be used to improve neurological worsening after stroke.
New treatments focusing on this end-point could be very interesting for
clinical practice.
However,more studies increasing the sample sizewith international
collaboration and robust replications will be needed to ﬁnd the
epigenetic regulations that could be associated with stroke.
Several studies are currently ongoing in this ﬁeld, mainly using
EWAS arrays due to the option to perform genome-wide unbiased
approaches. These studies will highlight the role of DNA methylation
in stroke (Table 1).
In addition, epigenetic treatment has been approved by regulatory
agencies for several conditions. The relevance of epigenetic treatment
in haematological malignancies (leukemia, lymphomas, myelodysplastic
syndromes,myeloma) have already been described in detail [62]. Several
agents that interfere with DNAmethylation-demethylation and histones
acetylation/deacetylation have been studied, and some (such as
azacytidine, decitabine, valproic acid and vorinostat) are already in
clinical use. In the current clinical setting, there are two classes of epige-
netic drugs, which act through inhibition of the enzymatic activities re-
sponsible for epigenetic transcriptional silencing: DNMTs and HDACs.
Importantly, one type of HDAC, HDAC9, has been associated with stroke
risk in several genome wide studies [9,13]. In addition, recent papers
using HDACs inhibitors have been associated with better functional
recovery in ischemic models of stroke [63]. This type of drugs could be
tested in stroke in the future if epigenetic associations with stroke risk
and stroke outcome are conﬁrmed.
The authors of the review “DNA methylation in ischemic stroke.
Update of last advances.” declare no disclosures and no conﬂict of
interest.
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